Every clinical trial generates a chain of interconnected documents, from the first protocol draft through the final clinical study report. When these documents fall out of sync, sites and sponsors face regulatory queries, delayed submissions, and compliance headaches. Recent data shows 76% of protocols now require at least one amendment, averaging 260 days from identification to final approval. During that period, sites often operate with different protocol versions for 215 days on average. The consequences of document inconsistency are not trivial. When your CSR describes endpoint definitions that differ from the SAP, or your consent form lists risks not captured in the investigator's brochure, regulatory inspections catch these discrepancies. ICH E6(R3), adopted by FDA in September 2025, makes sponsors explicitly responsible for documentation integrity across the entire trial lifecycle. For sites, this means understanding how protocol amendments trigger cascading updates to informed consent forms, investigator's brochures, and statistical analysis plans. A single substantial amendment can cost $535,000 for Phase III protocols and extend study timelines by three months. The key is treating clinical documents as an integrated system rather than isolated milestones.